Efficacy of modified atkins ketogenic diet in chronic cluster headache: An open-label, single-arm, clinical trial

Cherubino Di Lorenzo, Gianluca Coppola, Davide Di Lenola, Maurizio Evangelista, Giulio Sirianni, Paolo Rossi, Giorgio Di Lorenzo, Mariano Serrao, Francesco Pierelli

Research output: Contribution to journalArticle

Abstract

Introduction: Drug-resistant cluster headache (CH) is still an open clinical challenge. Recently, our group observed the clinical efficacy of a ketogenic diet (KD), usually adopted to treat drug-resistant epilepsies, on migraine. Aim: Here, we aim to detect the effect of KD in a group of drug-resistant chronic CH (CCH) patients. Materials and methods: Eighteen drug-resistant CCH patients underwent a 12-week KD (Modified Atkins Diet, MAD), and the clinical response was evaluated in terms of response (≥50% attack reduction). Results: Of the 18 CCH patients, 15 were considered responders to the diet (11 experienced a full resolution of headache, and 4 had a headache reduction of at least 50% in terms of mean monthly number of attacks during the diet). The mean monthly number of attacks for each patient at the baseline was 108.71 (SD = 81.71); at the end of the third month of diet, it was reduced to 31.44 (SD = 84.61). Conclusion: We observed for the first time that a 3-month ketogenesis ameliorates clinical features of CCH. Clinical Trial Registration: www.ClinicalTrials.gov, identifier NCT03244735.

Original languageEnglish
Article number64
JournalFrontiers in Neurology
Volume9
Issue numberFEB
DOIs
Publication statusPublished - Feb 12 2018

Keywords

  • Cluster headache
  • Drug resistance
  • Ketogenesis
  • Ketogenic diet
  • Ketone bodies
  • Modified Atkins diet

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint Dive into the research topics of 'Efficacy of modified atkins ketogenic diet in chronic cluster headache: An open-label, single-arm, clinical trial'. Together they form a unique fingerprint.

  • Cite this